← board
PYPD
PolyPid Ltd.distress 5/10 · elevated risk$4.17+4%today-25% from 52w high
Infectious Disease 1
Lead: Surgical Site Infection
Revenue
pre-revenue
Liquidity
$16M
Runway
0.6 yrs
Shares 1y
0%
Price & events
-13.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.3%
1D
-19.7%
1W
-16.4%
1M
-10.1%
3M
-12.8%
6M
+10.9%
1Y
+18.8%
2Y
-98.2%
5Y
-98.6%
All
Overview
- Market Cap
- $75.91M
- Enterprise Value
- $70.14M
- Volume
- 63.67K
- 52 Week Range
- $3.15 – $5.58
- Total Shares
- 18.20M
- Float Shares
- 10.91M
- Short %
- 0.60%
- % Held by Insiders
- 21.23%
- % Held by Institutions
- 34.85%
- RVOL
- 0.23x
- Beta
- 1.40
Pipeline stages · 1 programs
D-PLEX
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-04-14 | Phase 3 | D-PLEX | Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection | 800 | completed |
Catalyst news & presentations · 1
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-07-21HC Wainwright & Co.Buy
- 2026-02-11HC Wainwright & Co.Buy
- 2025-11-13Roth CapitalBuy
- 2025-08-14Craig-HallumBuy
- 2025-08-13HC Wainwright & Co.Buy
- 2025-06-18Roth CapitalBuy
Competitors — Surgical Site Infection
- none identified
Recent news
- 2026-07-22H.C. Wainwright reiterates Buy on PolyPid stock, $13 target - Investing.com
- 2026-07-21Azurity Pharmaceuticals Announces Plans To Commercialize D-PLEX100 In The United States And Canada Through Exclusive Partnership With PolyPid - marketscreener.com
- 2026-07-21PolyPid, Azurity sign surgical site infection drug deal - Reuters
- 2026-07-21PYPD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $13 - GuruFocus
- 2026-07-21PYPD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $13 - GuruFocus
- 2026-07-21PolyPid signs $320M deal with Azurity for D-PLEX100 in U.S., Canada - Investing.com South Africa
- 2026-07-21PolyPid signs $320M deal with Azurity for D-PLEX100 in U.S., Canada - Investing.com Nigeria
- 2026-07-21PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada - The Manila Times
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.